The position statement from cancer and bone societies updates recommendations from 2017 for managing bone loss and fracture ...

The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.

Postmenopausal women can use alternative drugs known as aromatase inhibitors, but those are not an option for younger ...

PIK3CA mutant cohort of the Phase 3 VIKTORIA-1 clinical trial is fully enrolledAdditional analysis of data from a Phase 1b clinical trial that included all patients treated with gedatolisib combined ...

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of patients treated with gedatolisib + palbociclib + fulvestrant ...

These Phase III results could enhance uptake of Eli Lilly's Verzenio alongside ET in the adjuvant breast cancer setting, if ...

Now four years into a first-in-class FDA approval for certain HR-positive, HER2-negative early breast cancers, Eli Lilly’s ...

Gedatolisib combined with fulvestrant, with or without palbociclib, significantly improved PFS in HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer. The triplet regimen reduced ...

Researchers appear to have found a solution for breast cancer patients who do not respond well enough to a common treatment.

Breast cancer is the most common cancer among women worldwide (WHO, 2023). The Dr. Margarete Fischer-Bosch Institute of ...

Doctors and a breast cancer survivor say it’s possible, depending on the treatment plan, including the type of mastectomy you ...